PMID- 16522339
OWN - NLM
STAT- MEDLINE
DCOM- 20060918
LR  - 20061115
IS  - 0168-1656 (Print)
IS  - 0168-1656 (Linking)
VI  - 125
IP  - 1
DP  - 2006 Aug 20
TI  - De novo design TNF-alpha antagonistic peptide based on the complex structure of 
      TNF-alpha with its neutralizing monoclonal antibody Z12.
PG  - 57-63
AB  - Tumor necrosis factor-alpha (TNF-alpha) antagonists have become therapeutic drugs 
      for immunological diseases including rheumatoid arthritis, inflammatory bowel 
      disease, Crohn's disease, etc. Low molecular weight synthetic peptides can mimic 
      the binding sites of TNF-alpha receptors and block the activity of TNF-alpha. 
      Based on the 3-D complex structure of TNF-alpha with its neutralizing monoclonal 
      antibody (Mab) Z12, an antagonistic peptide (AP) was rationally de novo designed. 
      The designed AP possessed similar structural character and potential bioactivity 
      with Mab Z12. AP could competitively inhibit the binding of Mab Z12 to TNF-alpha, 
      TNF-alpha-meditated caspase activation and TNF-alpha-induced cytotoxicity on 
      murine L929 cells with a dose-dependent fashion. This study highlights the 
      potential of computation-aided method for the design of novel peptides with the 
      ability to block the deleterious biological effects of TNF-alpha.
FAU - Qin, Weisong
AU  - Qin W
AD  - Institute of Basic Medical Sciences, P.O. Box 130 (3), Taiping Road, Beijing 
      100850, PR China.
FAU - Feng, Jiannan
AU  - Feng J
FAU - Li, Yan
AU  - Li Y
FAU - Lin, Zhou
AU  - Lin Z
FAU - Shen, Beifen
AU  - Shen B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060307
PL  - Netherlands
TA  - J Biotechnol
JT  - Journal of biotechnology
JID - 8411927
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Peptides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 3.4.22.- (Caspases)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/chemistry/immunology/*pharmacology
MH  - Caspases/metabolism
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects/immunology
MH  - Computer Simulation
MH  - Crystallography, X-Ray
MH  - *Drug Design
MH  - Enzyme Activation/drug effects
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Models, Molecular
MH  - Peptides/chemical synthesis/chemistry/*pharmacology
MH  - Protein Structure, Tertiary
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/chemistry/immunology
EDAT- 2006/03/09 09:00
MHDA- 2006/09/19 09:00
CRDT- 2006/03/09 09:00
PHST- 2005/11/19 00:00 [received]
PHST- 2005/12/30 00:00 [revised]
PHST- 2006/01/20 00:00 [accepted]
PHST- 2006/03/09 09:00 [pubmed]
PHST- 2006/09/19 09:00 [medline]
PHST- 2006/03/09 09:00 [entrez]
AID - S0168-1656(06)00101-5 [pii]
AID - 10.1016/j.jbiotec.2006.01.036 [doi]
PST - ppublish
SO  - J Biotechnol. 2006 Aug 20;125(1):57-63. doi: 10.1016/j.jbiotec.2006.01.036. Epub 
      2006 Mar 7.